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1. INTRODUCTION {#jmv24850-sec-0002}
===============

Asthma is a major childhood health risk. Acute asthma exacerbations remain a significant cause of morbidity in children and can lead to an accelerated decline in lung function,[1](#jmv24850-bib-0001){ref-type="ref"}, [2](#jmv24850-bib-0002){ref-type="ref"}, [3](#jmv24850-bib-0003){ref-type="ref"} which emphasises the importance of finding an appropriate preventive treatment. Epidemiologic studies have detected viral infections in more than 80% of school children with asthma exacerbations.[4](#jmv24850-bib-0004){ref-type="ref"} Of the respiratory viruses known to cause asthma exacerbations, between 60% and 70% are types of human rhinoviruses (HRV).[5](#jmv24850-bib-0005){ref-type="ref"}, [6](#jmv24850-bib-0006){ref-type="ref"} Moreover, one recent study showed that HRV was associated with a significantly increased risk of day‐to‐day asthma symptoms in children.[7](#jmv24850-bib-0007){ref-type="ref"} Understanding the role of HRV in acute asthma exacerbations may lead to interventions that will improve asthma management.

HRV is a single‐stranded RNA virus belonging to the genus *Enterovirus* and the family *Picornaviridae*. There are more than 100 classical HRV serotypes, which are divided into groups A (HRV‐A) and B (HRV‐B). Because of developments in molecular methods, recent studies have discovered over 50 new HRV strains referred to as HRV‐C.[8](#jmv24850-bib-0008){ref-type="ref"}, [9](#jmv24850-bib-0009){ref-type="ref"}, [10](#jmv24850-bib-0010){ref-type="ref"}, [11](#jmv24850-bib-0011){ref-type="ref"}, [12](#jmv24850-bib-0012){ref-type="ref"}, [13](#jmv24850-bib-0013){ref-type="ref"}, [14](#jmv24850-bib-0014){ref-type="ref"} Molecular epidemiological studies suggest that the dominant types are HRV‐A and HRV‐C, while HRV‐B is relatively rarely detected.[12](#jmv24850-bib-0012){ref-type="ref"}, [13](#jmv24850-bib-0013){ref-type="ref"}, [14](#jmv24850-bib-0014){ref-type="ref"} HRV‐C accounts for the majority of asthma attacks in children and causes more severe attacks than other HRV types and other viruses.[6](#jmv24850-bib-0006){ref-type="ref"}, [15](#jmv24850-bib-0015){ref-type="ref"}, [16](#jmv24850-bib-0016){ref-type="ref"}, [17](#jmv24850-bib-0017){ref-type="ref"}, [18](#jmv24850-bib-0018){ref-type="ref"}, [19](#jmv24850-bib-0019){ref-type="ref"} In our previous study, we found that HRV infection was associated with asthma in our region.[20](#jmv24850-bib-0020){ref-type="ref"} Some authors have demonstrated a close correlation between the HRV viral load and the disease severity in children with lower respiratory tract infections.[21](#jmv24850-bib-0021){ref-type="ref"}, [22](#jmv24850-bib-0022){ref-type="ref"}, [23](#jmv24850-bib-0023){ref-type="ref"} However, there have been no reports on the correlation of the viral load of different HRV species with the severity of asthma exacerbations.

The objective of the present study is to determine the prevalence of HRV infection in children with acute asthma exacerbations and the virus detection after acute asthma acute attacks as well as to investigate the relationship between different HRV types, viral load and severity of acute asthma exacerbations.

2. MATERIALS AND METHODS {#jmv24850-sec-0003}
========================

2.1. Study participants and sample collection {#jmv24850-sec-0004}
---------------------------------------------

During the study from March 2012 through November 2015, we enrolled inpatients with acute asthma exacerbations from the Department of Respiratory Medicine and outpatients from November 2014 to December 2015 at the Children\'s Hospital of Chongqing Medical University in China. Inclusion criteria were: children with asthma exacerbations and symptom onset ≤3 days and children with stable asthma to make up the control group. Exclusion criteria were as follows: children with chronic pulmonary disease, cardiopathy, metabolic and genetic diseases, or immunosuppression. The diagnosis of asthma and the severity of asthma exacerbations were assessed according to the guidelines of the Global Initiative for Asthma.

Nasopharyngeal aspirates (NPAs) and swabs (NPSs) were collected when the patients were admitted to our department, and clinical outcomes were recorded. We conducted a follow‐up study among these outpatients with asthma exacerbations and their NPSs were collected, and clinical outcomes were recorded when they visited the clinic again after 4 weeks. This study was approved by the Ethics Committee of the Children\'s Hospital of Chongqing Medical University. The informed consent for participation in the study was obtained from patients or legal guardians.

2.2. Definition of the severity of asthma exacerbations {#jmv24850-sec-0005}
-------------------------------------------------------

The severity of asthma exacerbations at presentation was determined using a previously validated reference standard for each subject by a paediatrician and divided into mild, moderate and severe groups.[24](#jmv24850-bib-0024){ref-type="ref"} Asthma symptom control was assessed with the Childhood Asthma Control Test[25](#jmv24850-bib-0025){ref-type="ref"} and divided into well‐controlled, not well‐controlled and poorly controlled groups according to the clinical symptom score.

2.3. HRV nucleotide sequence analysis and viral load detection {#jmv24850-sec-0006}
--------------------------------------------------------------

The 5′‐NCR (non‐coding region) and a partial sequence of the VP4/VP2 region was amplified by PCR as previously described.[26](#jmv24850-bib-0026){ref-type="ref"}, [27](#jmv24850-bib-0027){ref-type="ref"}, [28](#jmv24850-bib-0028){ref-type="ref"} The PCR products were sequenced by Shanghai Majorbio Bio‐Pharm Technology. The nucleotide sequences were compared with reference HRV strains obtained from GenBank for typing and to distinguish human enterovirus (HEV).

Amplification of HRV RNA by real‐time fluorescence quantitative PCR (RT‐PCR) was performed with the 5′‐NCR primers and probe.[29](#jmv24850-bib-0029){ref-type="ref"} RT‐PCR was performed using a TaKaRa OneStep PCR kit (Takara Biotechnology, Dalian, China).

2.4. Phylogenetic analysis {#jmv24850-sec-0007}
--------------------------

Phylogenetic analysis of HRV‐positive strains was performed as described previously using the neighbour‐joining (NJ) method,[27](#jmv24850-bib-0027){ref-type="ref"}, [30](#jmv24850-bib-0030){ref-type="ref"}, [31](#jmv24850-bib-0031){ref-type="ref"} and the reliability of the tree was estimated with 1000 bootstrap replications. We performed a phylogenetic tree of the VP4/VP2 coding region and 5′‐NCR using the CLUSTAL W program and MEGA 5.05 software. Sequences of reference strains were obtained from the GenBank database.

2.5. Detection of other respiratory viruses {#jmv24850-sec-0008}
-------------------------------------------

Respiratory syncytial virus types A and B (RSVA, RSVB), influenza virus A, B and C (IFVA, IFVB, IFVC), human coronaviruses (HCoV‐229E, HCoV‐OC43), human metapneumovirus (HMPV) and parainfluenza virus (PIV types 1‐4) were screened using nested PCR assays.[32](#jmv24850-bib-0032){ref-type="ref"}, [33](#jmv24850-bib-0033){ref-type="ref"} Adenovirus (ADV) was detected by means of multiplex PCR, and human bocavirus 1 (HBoV1) was screened using RT‐PCR.[34](#jmv24850-bib-0034){ref-type="ref"}, [35](#jmv24850-bib-0035){ref-type="ref"} All the specimens were analyzed using a commercial detection kit (TaKaRa Biotechnology, Dalian, China), according to the manufacturer\'s instructions.

2.6. Statistical analysis {#jmv24850-sec-0009}
-------------------------

Data were analyzed using the SPSS 17.0 software package. Categorical variables were compared using the chi‐squared or Fisher\'s exact test, and continuous variables were compared using Student\'s *t*‐test or the nonparametric Mann‐Whitney *U*‐test. Two‐sided *P*‐values of \<0.05 were considered statistically significant.

3. RESULTS {#jmv24850-sec-0010}
==========

3.1. Population demographics {#jmv24850-sec-0011}
----------------------------

A total of 143 inpatients with acute asthma exacerbations and another 131 outpatients, including 88 patients with asthma exacerbations and 43 controls with stable asthma were enrolled in this study. The age of inpatients ranged from 17 to 170 months (median, 45 months), and the male to female ratio was 84:59. The age of outpatients ranged from 22 to 144 months (median, 64 months), and the male to female ratio was 81:50. The percentage of mild asthma exacerbations was 21.7% (31/143), moderate was 53.1% (76/143) and severe was 25.2% (36/143) of inpatients. In outpatients, 20.5% (18/88) of exacerbations were mild, 58.0% (51/88) were moderate and 21.6% (19/88) were severe.

3.2. Virus detection {#jmv24850-sec-0012}
--------------------

Among inpatients, at least one virus was detected in 121 (84.6%) cases. HRV was identified in 72 samples (50.3%), and 65.3% (47/72) of the cases were identified as single HRV infections. Other common viruses included 36 RSV cases (25.2%), 13 PIV cases (9.1%), 12 HBoV1 cases (8.4%), 9 IFVA cases (6.3%), 6 ADV cases (4.2%), 2 HMPV cases (1.4%), and 8 HEV cases (5.6%). Among outpatients, respiratory viruses were detected in 45 (34.4%) subjects, and 40 were single infections. The rate of viral infections was 43.2% (38/88) in the group with asthma exacerbations. The HRV‐positive rate in the group with asthma exacerbations was 15.9% (14/88). The detection rate of both total virus and HRV of inpatients was significantly higher than that of outpatients (84.6% vs 43.2%; *P *\< 0.001 and 50.3% vs 15.9%; *P* \< 0.001). The detection rate of both total virus and HRV of inpatients was significantly higher than that of the stable asthma group (84.6% vs 16.3%; *P *\< 0.001 and 50.3% vs 2.3%; *P* \< 0.001). Furthermore, both the rate of total virus and HRV‐positive status in outpatients with asthma exacerbation was higher than that of the stable asthma group (43.2% vs 16.3%; *P* = 0.002 and 15.9% vs 2.3%; *P* = 0.045) (Table [1](#jmv24850-tbl-0001){ref-type="table"}).

###### 

Specific detected virus among all patients

            Inpatients   Outpatients   
  --------- ------------ ------------- ----------
  HRV       72 (50.3)    14 (15.9)     1 (2.3)
  HRV‐A     25 (17.5)    3 (3.4)       1 (2.3)
  HRV‐B     5 (3.5)      1 (1.1)       0 (0)
  HRV‐C     42 (29.4)    9 (10.2)      0 (0)
  Untyped   0 (0)        1 (1.1)       0 (0)
  RSV       36 (25.2)    4 (4.5)       0 (0)
  RSVA      23 (16.1)    3 (3.4)       0 (0)
  RSVB      13 (9.1)     1 (1.1)       0 (0)
  PIV       13 (9.1)     9 (10.2)      3 (7.0)
  PIV3      8 (5.6)      5 (5.7)       3 (7.0)
  PIV4      5 (3.5)      4 (4.5)       0 (0)
  IFV       9 (6.3)      3 (3.4)       1 (2.3)
  IFVA      9 (6.3)      1 (1.1)       0 (0)
  IFVB      0 (0)        2 (2.3)       1 (2.3)
  HBoV1     12 (8.4)     3 (3.4)       2 (4.7)
  ADV       6 (4.2)      1 (1.1)       0 (0)
  HMPV      2 (1.4)      1 (1.1)       0 (0)
  HCoV      0 (0)        1 (1.1)       0 (0)
  HEV       8 (5.6)      2 (2.3)       0 (0)
  Total     121 (84.6)   38 (43.2)     7 (16.3)

HRV, human rhinovirus; RSV, respiratory syncytial virus; PIV, parainfluenza virus; IFV, influenza virus; HBoV1, human bocavirus type 1; ADV, adenovirus; HMPV, human metapneumovirus; HCoV, human coronaviruses; HEV, human enterovirus.
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3.3. HRV types and asthma exacerbations {#jmv24850-sec-0013}
---------------------------------------

In hospitalized children, the VP4/VP2 region was successfully amplified in 56 samples: HRV‐A was identified in 35.7% of samples (20/56), HRV‐B in 8.9% (5/56), and HRV‐C in 55.4% (31/56). The number of HRV‐C‐positive cases was more than those of HRV‐A and HRV‐B (*P* = 0.037 and *P* \< 0.001). The HRV‐C detection rate in severe groups was significantly higher than that of the mild group (36.1% vs 6.5%; *P* = 0.004). The rates of HRV‐A and HRV‐B‐positivity rated showed no different in the three severity groups (*P* = 0.596 and *P* = 0.731). The VP4/VP2 sequence was amplified in one outpatient, while others could not be obtained because of low amplicon yield, and 5′‐NCR sequences from the remaining HRV‐positive specimens were used for typing. The majority of those in the group with acute asthma exacerbations (64.3%; 9/14) was infected with an HRV‐C, 21.4% (3/14) was infected with HRV‐A, only one patient was infected with HRV‐B and one was untyped (Table [2](#jmv24850-tbl-0002){ref-type="table"}). Because of the small number of outpatients with HRV in the different severity groups, comparisons were not performed.

###### 

HRV types and severity of acute asthma exacerbations in children

  Inpatients (*n* = 143) *N* (%)   Outpatients (*n* = 88) *N* (%)                                                                                                              
  -------------------------------- -------------------------------- --------- ----------------------------------------------------- --------------------- ---------- --------- ----------
  Severity                         HRV‐A                            HRV‐B     HRV‐C                                                 Severity              HRV‐A      HRV‐B     HRV‐C
  Mild (*n* = 31)                  6 (19.4)                         1 (3.2)   2 (6.5)                                               Mild (*n* = 18)       0 (0)      0 (0)     4 (22.2)
  Moderate (*n* = 76)              9 (11.8)                         2 (2.6)   16 (21.1)                                             Moderate (*n* = 51)   1 (2.0)    1 (2.0)   3 (5.9)
  Severe (*n* = 36)                5 (13.9)                         2 (5.6)   13 (36.1)[^\*^](#jmv24850-note-0003){ref-type="fn"}   Severe (*n* = 19)     2 (10.5)   0 (0)     2 (10.5)

HRV indicates human rhinovirus.

There were more HRV‐C positive inpatients in the severe asthma exacerbation than in the mild exacerbation group (*P* = 0.004).
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3.4. Clinical features of HRV positive and negative patients {#jmv24850-sec-0014}
------------------------------------------------------------

The percentage of severe acute asthma exacerbations in the HRV‐positive group was higher than that of the HRV‐negative group (*P* = 0.032), while the number of patients with fever was less than that in the HRV‐negative group (*P* = 0.007). The white blood cell counts and neutrophil percentages were both significantly higher in the HRV‐positive group (*P* = 0.041 and *P *= 0.043, respectively). The other features between the HRV‐positive and HRV‐negative groups had no statistically significant difference. All the clinical features between single HRV‐A‐positive and HRV‐C‐positive groups had no statistically significant difference (Table [3](#jmv24850-tbl-0003){ref-type="table"}). The percentage of familial eczema and neutrophils were significantly higher in the group of outpatients with HRV infection than in the group without HRV infection (*P* = 0.049 and *P* = 0.030, respectively). The clinical characteristics of HRV‐A and HRV‐C‐positive outpatients showed that the percentage of allergic rhinitis in the HRV‐C‐positive group was significantly higher than that of the HRV‐A group (*P* = 0.045) (Table [4](#jmv24850-tbl-0004){ref-type="table"}).

###### 

Comparison of clinical features between HRV‐positive and HRV‐negative inpatients with asthma exacerbations

                                            HRV *N* (%)     HRV single infection *N* (%)                                               
  ----------------------------------------- --------------- ------------------------------ ----------- --------------- --------------- -------
  Male:female                               23:24           47:24                          0.062       5:11            16:13           0.124
  Age (median, month)                       40              43                             0.658       48              37              0.109
  History of eczema                         13 (27.7)       26 (36.6)                      0.311       4 (25.0)        8 (27.6)        1.000
  History of allergic conditions            8 (17.0)        18 (25.4)                      0.285       3 (18.8)        5 (17.2)        1.000
  Familial asthma                           28 (59.6)       43 (60.6)                      0.858       10 (62.5)       16 (55.2)       0.634
  Cough                                     47 (100)        71 (100)                       ‐           16 (100)        29 (100)        ‐
  Rhinorrhea                                8 (17.0)        12 (16.9)                      0.986       5 (31.3)        3 (10.3)        0.177
  Expectoration                             34 (72.3)       47 (66.2)                      0.481       11 (68.8)       21 (72.4)       1.000
  Wheezing                                  41 (87.2)       58 (81.7)                      0.422       14 (87.5)       26 (89.7)       1.000
  Fever                                     14 (29.8)       39 (54.9)                      **0.007**   5 (31.3)        9 (31.0)        1.000
  Severe exacerbation                       16 (34.0)       12 (16.9)                      **0.032**   5 (31.3)        10 (34.5)       0.826
  Length of hospitalization (median, day)   5 (3‐8)         5 (2‐16)                       0.388       5 (3‐6)         5 (4‐8)         0.250
  White blood cell (×10^9^/L)               12.38 ± 5.13    10.77 ± 4.87                   **0.041**   12.16 ± 5.71    12.58 ± 5.05    0.868
  Neutrophils (%)                           64.70 ± 20.27   56.44 ± 21.95                  **0.043**   64.50 ± 21.18   65.31 ± 19.85   0.915
  Lymphocyte (%)                            30.60 ± 18.50   39.03 ± 21.19                  **0.031**   29.63 ± 18.42   30.62 ± 18.47   0.859
  CRP \> 8 mg/L (%)                         6 (12.8)        8 (11.3)                       0.805       3 (18.8)        3 (10.3)        0.737
  Platelet (×10^9^/L)                       333 ± 102       321 ± 94                       0.308       319 ± 106       337 ± 102       0.887

HRV indicates human rhinovirus. Categorical variables were compared using the chi‐squared test, and the continuous variables were compared using the Student\'s *t*‐test or the nonparametric Mann‐Whitney *U*‐test. Two‐sided *P*‐values of \< 0.05were considered statistically significant.
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###### 

Comparison of clinical features between HRV‐positive and HRV‐negative outpatients with asthma exacerbations

                                 HRV *N* (%)      HRV‐positive *N* (%)                                               
  ------------------------------ ---------------- ---------------------- ----------- --------------- --------------- -----------
  Male:female                    8:6              49:25                  0.729       2:1             5:4             1.000
  Age (median, month)            60               64                     0.941       54              56              0.926
  History of allergic rhinitis   12 (85.7)        49 (66.2)              0.257       1 (33.3)        9 (100)         **0.045**
  History of eczema              5 (35.7)         24 (32.4)              1.000       1 (33.3)        4 (44.4)        1.000
  Familial allergic rhinitis     3 (21.4)         10 (13.5)              0.723       1 (33.3)        2 (22.2)        1.000
  Familial eczema                3 (21.4)         3 (4.1)                **0.049**   1 (33.3)        2 (22.2)        1.000
  Familial asthma                1 (7.1)          12 (16.2)              0.641       0 (0)           1 (11.1)        1.000
  Passive smoking                6 (42.9)         18 (24.3)              0.271       0 (0)           5 (55.6)        0.310
  Cough                          13 (92.9)        71 (95.9)              0.507       3 (100)         8 (88.9)        1.000
  Expectoration                  6 (42.9)         22 (29.7)              0.513       2 (66.7)        3 (33.3)        0.735
  Wheezing                       13 (92.9)        57 (77.0)              0.324       3 (100)         8 (88.9)        1.000
  Fever                          1 (7.1)          1 (1.4)                0.294       0 (0)           1 (11.1)        1.000
  Tachypnea                      6 (42.9)         14 (18.9)              0.107       0 (0)           5 (55.6)        0.310
  White blood cell (×10^9^/L)    10.22 ± 3.66     9.85 ± 3.06            0.698       9.49 ± 2.76     11.26 ± 3.47    0.307
  Neutrophils (%)                56.87 ± 13.93    46.95 ± 12.63          **0.030**   60.67 ± 17.21   58.43 ± 11.39   0.540
  Eosinophils (%)                6.26  ± 3.68     6.48 ± 3.94            0.791       8.33 ± 6.81     5.39 ± 2.30     0.757
  FEV~1~% predicted              91.68 ± 12.78    92.69 ± 14.12          0.913       92.70 ± 0       95.30 ± 12.89   0.655
  PEF% predicted                 93.35  ± 11.39   80.25 ± 19.47          0.147       75.30 ± 0       96.20 ± 12.08   0.180
  Positive skin tests            7 (50.0)         42 (58.1)              0.431       1 (33.3)        6 (66.7)        0.735

FEV~1~, forced expiratory volume in one second; PEF, peak expiratory flow. Two‐sided *P*‐values of \< 0.05were considered statistically significant.

© 2017 Wiley Periodicals, Inc.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

3.5. Seasonality of HRV infections and asthma exacerbations {#jmv24850-sec-0015}
-----------------------------------------------------------

The frequency of asthma exacerbations among HRV‐positive inpatients was calculated as 48.0% (12/25) in spring, 44.0% (11/25) in summer, 60.6% (43/71) in autumn, and 27.3% (6/22) in winter during the study period by merging the same month. HRV‐A was mainly detected in September and February (45.5% and 33.3%, respectively), while HRV‐C was mainly detected in November and April (70.0% and 55.6%, respectively) (Fig. [1](#jmv24850-fig-0001){ref-type="fig"}).

![Seasonal incidence (rate of positive samples) by month of HRV‐A, HRV‐B, and HRV‐C. Data was combined from 3 years and bar graph represents the detection rate of the three HRV types](JMV-90-219-g001){#jmv24850-fig-0001}

3.6. HRV viral load and severity of asthma exacerbations {#jmv24850-sec-0016}
--------------------------------------------------------

The genome viral load of 62 inpatients infected with HRV has been detected, and 10 cases have not been detected using the 5′‐NCR primers and probe. The median age of these inpatients was 45 months, and the male to female ratio was 32:30. The genome viral load ranged from 2.2 to 2.9 × 10^7^ copies/mL. However, there was no significant difference of HRV total viral load among the different severities of asthma exacerbations (Fig. [2](#jmv24850-fig-0002){ref-type="fig"}A). The viral load of HRV‐A in the severe group was higher than that in the mild group (mean, 2.5 × 10^5^ copies/mL vs 1.7 × 10^3^ copies/mL; *P* \< 0.001) and the moderate group (mean, 2.5 × 10^5^ copies/mL vs 2.1 × 10^3^ copies/mL; *P* = 0.022) (Fig. [2](#jmv24850-fig-0002){ref-type="fig"}B). However, the HRV‐C viral load among the three groups showed no significant difference (Fig. [2](#jmv24850-fig-0002){ref-type="fig"}C). Moreover, the viral loads of HRV‐A and HRV‐B were significantly higher than the HRV‐C viral load regardless of the severity (mean, 8.5 × 10^3^ copies/mL vs 2.5 × 10^2^ copies/mL; *P* \< 0.001; mean, 1.6 × 10^4^ copies/mL vs 2.5 × 10^2^ copies/mL; *P* = 0.014) (Fig. [2](#jmv24850-fig-0002){ref-type="fig"}D). The viral load of HRV‐A was higher than HRV‐C in the group with severe asthma exacerbations (mean, 2.5 × 10^5^ copies/mL vs 1.6 × 10^2^ copies/mL; *P* \< 0.0001) (Fig. [2](#jmv24850-fig-0002){ref-type="fig"}E). Because of the small number of outpatients with HRV in the different severity groups, the comparisons between different HRV types viral load and severity of disease were excluded. Even so, the total viral load of HRV was compared. And the HRV‐A total viral load was significantly higher than that of HRV‐C (mean, 9.4 × 10^3^ copies/mL vs 7.1 × 10^2^ copies/mL; *P* = 0.036).

![Relationship between HRV viral load and severity of asthma exacerbations among inpatients. A: HRV total viral load among the three groups shows no significant difference. B: HRV‐A viral load in severe group was significantly higher than in the mild and moderate groups (*P* \< 0.001 and *P* = 0.022). C: HRV‐C viral load the among three groups shows no significant difference. D: HRV‐A and HRV‐B viral load were significantly higher than HRV‐C regardless of the severity (*P* \< 0.001 and *P* = 0.014). E: In the severe group, HRV‐A viral load was significantly higher than HRV‐C (*P* \< 0.0001). The comparison of viral load was conducted by nonparametric Mann‐Whitney *U*‐test](JMV-90-219-g002){#jmv24850-fig-0002}

3.7. Phylogenetic analysis {#jmv24850-sec-0017}
--------------------------

Figure [3](#jmv24850-fig-0003){ref-type="fig"} shows the phylogenetic tree of inpatients based on the nucleotide sequences of the VP4/VP2 coding region. The 56 HRV‐positive samples from inpatients were grouped into 37 HRV genotypes, 31 HRV‐C samples were grouped into 19 HRV‐C genotypes, 20 HRV‐A samples were grouped into 13 HRV‐A genotypes, and 5 HRV‐B samples were grouped into 5 HRV‐B genotypes. There were six (10.7%) strains which could be designated into novel genotypes and temporarily named HRV‐C53 and four (7.1%) HRV‐A20 strains, the two predominant genotypes, followed by HRV‐C21 three (5.4%), HRV‐A49 three (5.4%) (Fig. [3](#jmv24850-fig-0003){ref-type="fig"}). The clinical characteristics of HRV‐C53 and HRV‐A20‐positive inpatients are summarized in Table [5](#jmv24850-tbl-0005){ref-type="table"}, the severity of their asthma exacerbations was moderate or severe and there were five cases of dyspnea. Figure [4](#jmv24850-fig-0004){ref-type="fig"} shows the phylogenetic tree of outpatients based on the nucleotide sequences of the 5′‐NCR, and all the HRV‐positive samples were grouped into 15 genotypes. One sample was amplified by the VP4/VP2 region and divided into HRV‐C22 (Accession number: JN621242). The distribution of outpatients' genotypes had no obvious regularity and neither HRV‐C53 nor HRV‐A20 was found.

![Phylogenetic analysis of the HRV VP4/VP2 coding region from inpatients using the neighbour‐joining method with 1000 bootstrap replicates with MEGA5.05; branches showing \>70% bootstrap support are indicated. The strains in this study are marked with CQ (Chongqing) and HRV‐A labeled ♦, HRV‐B labeled ●, and HRV‐C labeled ▴](JMV-90-219-g003){#jmv24850-fig-0003}

###### 

Clinical features of inpatients with HRV‐C53 and HRV‐A20 infections

  Sample   Genotype   Age/sex (year‐month)   Sample collection time   Symptoms                                               Severity
  -------- ---------- ---------------------- ------------------------ ------------------------------------------------------ ----------
  CQ7356   C53        2‐7/Male               2014/10                  Fever/cough/wheezing/dyspnea                           Severe
  CQ7375   C53        3‐4/Female             2014/10                  Fever/cough/expectoration/wheezing                     Moderate
  CQ7465   C53        2‐9/Male               2014/11                  Fever/cough/expectoration/wheezing/dyspnea             Severe
  CQ7467   C53        2‐9/Female             2014/11                  Cough/expectoration/wheezing/dyspnea                   Severe
  CQ7547   C53        2‐1/Female             2014/11                  Fever/cough/expectoration/wheezing/dyspnea/diarrhoea   Severe
  CQ7774   C53        2‐3/Male               2015/01                  Cough/expectoration/wheezing                           Moderate
  CQ8589   A20        7‐0/Female             2015/09                  Cough/expectoration/wheezing                           Moderate
  CQ8619   A20        4‐0/Female             2015/09                  Cough/wheezing/dyspnea                                 Severe
  CQ8625   A20        2‐7/Female             2015/10                  Cough/expectoration/wheezing                           Moderate
  CQ8626   A20        3‐0/Male               2015/10                  Fever/cough/expectoration/wheezing/diarrhoea           Moderate

CQ indicates Chongqing.
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3.8. Follow‐up of outpatients {#jmv24850-sec-0018}
-----------------------------

All the HRV‐positive outpatients with acute asthma exacerbations participated in the follow‐up, and only one case was infected with RSVA within 4 weeks after first the visit. The remaining patients tested negative, and the severity of the disease was well‐controlled. Another 23 patients were without HRV during the first visit, while after 4 weeks, five cases of acute asthma exacerbations appeared again and among them, four patients were infected with HRV (Table [6](#jmv24850-tbl-0006){ref-type="table"}).

###### 

Details of follow‐up after 4 weeks in outpatients with asthma exacerbations

  Sample   Age/sex (year‐month)   First visit pathogen   Follow‐up of condition   Follow‐up of pathogen
  -------- ---------------------- ---------------------- ------------------------ -----------------------
  CQ2      1‐10/Female            HRV‐C                  Well controlled          Negative
  CQ9      4‐0/Male               HRV‐C                  Well controlled          Negative
  CQ10     4‐4/Female             HRV‐C                  Well controlled          Negative
  CQ11     5‐4/Male               HRV‐C                  Re‐exacerbation          RSVA
  CQ15     4‐8/Female             HRV‐C                  Well controlled          Negative
  CQ16     8‐0/Male               HRV‐C                  Well controlled          Negative
  CQ40     3‐8/Female             HRV‐C                  Well controlled          Negative
  CQ49     7‐8/Female             HRV‐C                  Well controlled          Negative
  CQ64     7‐2/Male               HRV‐C/IFVB             Well controlled          Negative
  CQ44     3‐7/Male               HRV‐A                  Well controlled          Negative
  CQ45     12‐11/Female           HRV‐A                  Well controlled          Negative
  CQ54     4‐6/Female             HRV‐A/HBoV1            Well controlled          Negative
  CQ104    5‐11/Female            HRV‐B                  Well controlled          Negative
  CQ29     8‐7/Male               HRV‐untyped            Well controlled          Negative
  CQ14     8‐0/Female             RSVA                   Re‐exacerbation          HRV‐A
  CQ21     12‐0/Female            IFVA                   Well controlled          Negative
  CQ96     7‐2/Female             PIV3                   Well controlled          Negative
  CQ98     11‐3/Male              PIV3                   Well controlled          Negative
  CQ24     2‐10/Female            PIV4                   Well controlled          Negative
  CQ23     5‐2/Female             RSVA/PIV4              Well controlled          Negative
  CQ12     5‐11/Male              Negative               Re‐exacerbation          HRV‐C/IFVA
  CQ120    5‐0/Female             Negative               Re‐exacerbation          HRV‐untyped
  CQ128    8‐9/Female             Negative               Re‐exacerbation          HRV‐A/RSVA
  CQ31     2‐9/Female             Negative               Re‐exacerbation          Negative
  CQ34     1‐5/Male               Negative               Well controlled          Negative
  CQ37     4‐1/Male               Negative               Well controlled          Negative
  CQ42     8‐7/Female             Negative               Well controlled          Negative
  CQ51     8‐7/Female             Negative               Well controlled          Negative
  CQ60     3‐3/Male               Negative               Well controlled          Negative
  CQ72     5‐9/Female             Negative               Well controlled          Negative
  CQ73     3‐9/Female             Negative               Well controlled          Negative
  CQ112    5‐4/Male               Negative               Well controlled          Negative
  CQ116    5‐2/Female             Negative               Well controlled          Negative
  CQ117    2‐5/Male               Negative               Well controlled          Negative
  CQ119    4‐0/Female             Negative               Well controlled          Negative
  CQ125    7‐11/Female            Negative               Well controlled          Negative
  CQ126    4‐7/Female             Negative               Well controlled          Negative
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4. DISCUSSION {#jmv24850-sec-0019}
=============

HRV is an important cause of both upper and lower respiratory illnesses as well as acute exacerbations of childhood asthma. In our study, HRV was the most common viral pathogen that induced asthma exacerbations in children. This finding is consistent with previous studies,[6](#jmv24850-bib-0006){ref-type="ref"}, [11](#jmv24850-bib-0011){ref-type="ref"}, [15](#jmv24850-bib-0015){ref-type="ref"} and the detection rate of HRV in asthma exacerbation patients was significantly higher than that in the stable asthma group. The detection rate of HRV was 50.3% among inpatients, while some authors reported the rate to be between 60% and 70%. The reason for the difference was that their studies were performed among school‐aged children, and the region was different.[5](#jmv24850-bib-0005){ref-type="ref"}, [6](#jmv24850-bib-0006){ref-type="ref"} Among the inpatients, 34.7% (25/72) were diagnosed with HRV co‐infection, 52% (13/25) of cases were diagnosed as co‐infection with RSV, 24% (6/25) of cases were diagnosed as co‐infection with HBoV1, 16% (4/25) of cases were diagnosed as PIV, 8% (2/25) of cases were diagnosed as ADV, 8% (2/25) of cases were diagnosed as IFVA and 4% (1/25) of cases were diagnosed as HEV. The median age was 43 months, and 64% (16/25) were in the moderate to severe category groups. The incidence of HRV in outpatients was lower than that in hospitalized children, but the methods of virus detection are consistent, which may be because the severity of outpatients was relatively mild or onset of other causes, such as medication, is irregular. The detection rate of RSV was 25.2% (36/143) among inpatients, and 13 cases were diagnosed as co‐infection with HRV, 7 cases were diagnosed as co‐infection with other viruses (PIV/ADV/HEV/IFVA) and others were diagnosed as single infections. The median age was 33 months, and 69.5% (25/36) were in the moderate to severe category groups.

Previous studies have demonstrated that neutrophils are the predominant inflammatory cell in the airways of patients with acute asthma exacerbation, and experimental HRV infection has been shown to increase airway neutrophilic inflammation in asthmatic subjects.[36](#jmv24850-bib-0036){ref-type="ref"}, [37](#jmv24850-bib-0037){ref-type="ref"}, [38](#jmv24850-bib-0038){ref-type="ref"} Our clinical and laboratory results, combined with haemograms, indicated that acute viral infections, especially HRV, need to be considered during popular seasons in children with acute asthma attacks, even though the percentage of neutrophils does not exceed 70%.

Although this study only included data from 3 years, we showed both annual and seasonal variation in HRV types. The seasonal prevalence of asthma exacerbations was consistent with HRV infection and occurred mainly in autumn. Our results were similar to those presented in earlier reports, which have associated the September peak in asthma hospitalizations with rhinovirus circulation.[39](#jmv24850-bib-0039){ref-type="ref"}, [40](#jmv24850-bib-0040){ref-type="ref"} Our subtropical climate was the reason for the difference.

HRV‐C attracts special clinical interest because they can cause more severe illnesses, requiring hospitalization in infants and children, compared with the HRV‐A or HRV‐B, and are closely associated with acute asthma exacerbations.[15](#jmv24850-bib-0015){ref-type="ref"}, [41](#jmv24850-bib-0041){ref-type="ref"}, [42](#jmv24850-bib-0042){ref-type="ref"} Our study has demonstrated that the HRV‐C detection rate was greater than 50% among inpatients and outpatients, which supports the hypothesis that HRV‐C was to the most common cause of acute asthma attacks in children. Among inpatients, HRV‐C was responsible for not only the majority of acute asthma attacks compared to other HRV species or other known viruses, but was also more frequently involved in severe asthma attacks.

The phylogenetic analysis showed that HRV‐C53 and HRV‐A20 were the predominant strains among inpatients. The HRV‐C53 genotype mainly occurred in October and November 2014, HRV‐A20 occurred in September and October 2015 in Chongqing, China and caused more severe clinical manifestations. HRV‐C53 was once known as HRV‐Cpat10, which was provisionally assigned types (designated "pat"), and we did not find other literature reporting the relationships between asthma attacks and HRV‐C53 or HRV‐Cpat10.[27](#jmv24850-bib-0027){ref-type="ref"}, [28](#jmv24850-bib-0028){ref-type="ref"} However, the two genotypes were not found in outpatients, and these results supported that HRV‐C53 and HRV‐A20 were more common in severe asthma attacks.

Some observations suggested that people with asthma might be at risk for higher viral loads and symptoms affecting their respiratory tract during HRV infection.[43](#jmv24850-bib-0043){ref-type="ref"} Our study confirmed that HRV‐A viral load in the severe asthma exacerbations group was significantly higher than that of the mild and moderate groups, while HRV‐C was not. This result indicates that HRV‐A viral load is associated with the severity of asthma exacerbations but HRV‐C is not. Additionally, in severe asthma exacerbations, the HRV‐A viral load was higher than that of HRV‐C, which suggested that the mechanisms of the exacerbations were not similar.

We further compared clinical features between single HRV‐A positive and HRV‐C positive inpatients and no difference was found between the two groups. However, the number of outpatients with allergic rhinitis increased in the HRV‐C infection group and whether indicated those asthmatic children who complicated with allergic rhinitis were tend to infect HRV‐C even appear exacerbations. The findings highlight the fact that physicians and parents should provide preventive management to those children during the peak season of HRV‐C infections.

HRV‐C species do not grow in standard cell cultures used for virus isolation, which limits the research on their biological characteristics. According to our understanding of the mechanism, it is possible that the HRV‐C receptor is distinct from the intercellular adhesion molecule 1 (ICAM‐1) and low‐density lipoprotein receptor (LDLR) family members used by HRV‐A.[44](#jmv24850-bib-0044){ref-type="ref"}, [45](#jmv24850-bib-0045){ref-type="ref"} The latest research has reported that human cadherin‐related family member 3 (CDHR3), a member of the cadherin family of transmembrane proteins, mediates HRV‐C entry into host cells, and an asthma‐related mutation (rs6967330) in this gene is associated with enhanced viral binding and replication. CDHR3 mutations result in susceptibility to childhood asthma with severe exacerbations.[46](#jmv24850-bib-0046){ref-type="ref"}, [47](#jmv24850-bib-0047){ref-type="ref"} These findings suggest that CDHR3 is a functional receptor for HRV‐C and explain asthma exacerbations are commonly induced by HRV‐C. Additionally, different HRV types may have different replications and induce diversified cytokines and chemokines, which contribute to varying illness severity.[48](#jmv24850-bib-0048){ref-type="ref"} Further study is needed to investigate the mechanism of HRV‐A and HRV‐C resulting in different illness severities.

Through the follow‐up among outpatients with asthma exacerbations, HRV persisted for no more than 4 weeks in the nasopharynx, and their symptoms or signs of disease appeared well‐controlled. Some authors have reported that HRV infections in infants rarely result in persistence of RNA beyond 30 days.[49](#jmv24850-bib-0049){ref-type="ref"} Further studies of large samples are required to confirm these findings. Some asthma exacerbation cases may be caused by other respiratory viruses or may present without viral infection at the first visit, while asthma attacks caused by HRV infections may appear again after 4 weeks.

In summary, the virus most frequently detected in asthma exacerbations appears to be HRV, primarily HRV‐C, which commonly occurs in severe asthma exacerbations. HRV‐A with high viral load leads to severe asthma exacerbations, and HRV‐C viral load and disease severity have no significant correlation. The novel genotypes HRV‐C53 and HRV‐A20 have been found to be predominant strains that cause more severe clinical manifestations. Additionally, we followed up on HRV changes in the airways of asthmatic children, and HRV RNA was found to persist for no longer than 4 weeks. Overall, our results provide some theoretical evidence for the prevention of childhood asthma exacerbations and improving asthma management.
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